We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
BioTrove Establishes Supply Agreement for OpenArray™ Technology with OncoMethylome Sciences
News

BioTrove Establishes Supply Agreement for OpenArray™ Technology with OncoMethylome Sciences

BioTrove Establishes Supply Agreement for OpenArray™ Technology with OncoMethylome Sciences
News

BioTrove Establishes Supply Agreement for OpenArray™ Technology with OncoMethylome Sciences

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "BioTrove Establishes Supply Agreement for OpenArray™ Technology with OncoMethylome Sciences"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

BioTrove, Inc. has announced an agreement with OncoMethylome Sciences for supply and use of BioTrove's OpenArray™ PCR screening technology in the development of DNA gene methylation cancer biomarkers.

"We look forward to enhancing our pharmacogenomic services with the BioTrove OpenArray system, which enables us to test our many proprietary methylation markers on clinical samples in a fast, high-throughput manner," said Wim Van Criekinge, Vice President, Biomarker and Pharmacogenomics Research, OncoMethylome.

Under the terms of the multi-year agreement, BioTrove will supply OncoMethylome with OpenArray nanoplates and instrumentation for use in research and development of DNA methylation-based biomarkers. Financial terms were not disclosed.

Gene methylation, a control mechanism that regulates gene expression in DNA, has become an important area of cancer diagnostics research. OncoMethylome products are designed to detect cancer cells and predict their response to cancer therapy by identifying specific methylation markers in patient DNA samples through PCR.

"Our supply agreement with OncoMethylome confirms the value of OpenArray technology in accelerating the development of diagnostic biomarkers - an important research area impacting patient health and treatment," said Al Luderer, Ph.D., president and CEO, BioTrove.

"Our company mission is to advance life science research through our technology, and we are especially pleased OncoMethylome has adopted our system for this purpose," Luderer added.

Advertisement